Top Dutasteride Brands: A Guide to the Best Options

Dutasteride is a medication commonly used to treat conditions such as enlarged prostate, and several pharmaceutical brands offer high-quality formulations. Among the most renowned brands for dutasteride are Avodart and Duprost, both known for their effectiveness and consistency in treatment outcomes. Cipla and Zydus also produce duasteride, gaining popularity due to competitive pricing and wide availability. For a comprehensive guide on these brands and others, along with insights into their specific benefits, continue reading below.

Illustration of dutasteride

Best brands of dutasteride in 2025

Avodart

Avodart, produced by GlaxoSmithKline, is a leading brand for dutasteride, a medication primarily used to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It works by inhibiting the 5 alpha-reductase enzyme, thereby reducing the production of dihydrotestosterone (DHT), a hormone implicated in prostate enlargement. Avodart had significant annual sales, approximately $467 million in the United States as of 2015. The drug is available in 0.5 mg soft gelatin capsules and is known for its efficacy in alleviating symptoms such as increased frequency of urination and difficulty starting or completing urination. For detailed information, visit the Avodart drug overview on RxList.

Duprost

Duprost, a brand of dutasteride produced by Cipla Ltd, is a highly effective treatment for benign prostatic hyperplasia (BPH) and hair loss, renowned for its potent 5-alpha reductase inhibition, which can reduce DHT levels by up to 98%. Approved for medical use in 2001 and later for hair loss in South Korea in 2009 and Japan in 2015, Duprost is available in capsule form and can be taken with or without food. It is notable for its long elimination half-life of 4-5 weeks and is primarily eliminated through the feces. Common side effects include decreased libido, ejaculation disorder, and breast tenderness in males. Duprost is widely available and has been a popular choice due to its efficacy and availability in generic formulations since the patent expiration in 2015.

Dutagen

Dutasteride, often marketed under the brand name Avodart, is a highly effective medication for treating benign prostatic hyperplasia (BPH) and, in some cases, scalp hair loss. It is a 5a-reductase inhibitor that reduces dihydrotestosterone (DHT) levels by up to 98%, significantly more than finasteride, which reduces DHT by 65-70%. Approved by the FDA in 2001, dutasteride has been widely prescribed, with over 1 million prescriptions in the US in 2018 alone. The drug is known for its long elimination half-life of 4-5 weeks and is available in both brand and generic forms since the patent expired in 2015. Major pharmaceutical companies like GSK, Teva, and Mylan are key producers of dutasteride.

Veltam

Veltam, a notable brand, is recognized for its high-quality production of dutasteride, often combined with tamsulosin to treat benign prostatic hyperplasia and other urinary issues. In recent exports, Veltam Plus, which contains 0.4mg of tamsulosin and 0.5mg of dutasteride, has seen significant demand, with shipments increasing by 40% sequentially from January to February 2024. This combination product is widely exported, with India being a major exporter, contributing to over 7,000 shipments annually. The bioavailability of tamsulosin in Veltam Plus is enhanced by 30% when taken with food, and the maximum plasma concentration increases by 40-70%. This formulation has been approved and marketed in several regions, including the United States and Europe.

Dutas

Dutasteride, marketed under the brand name Avodart among others, is a highly effective medication for treating benign prostatic hyperplasia (BPH), with dutasteride reducing serum DHT levels by up to 90% within 1 to 2 weeks of daily dosing. It is a competitive and specific inhibitor of both type 1 and type 2 5a-reductase isoenzymes, achieving a reduction in circulating DHT levels of up to 98%. Approved by the FDA in 2001, dutasteride has been widely prescribed, with over 1 million prescriptions in the US in 2018. The drug is available in a generic form since the patent expired in 2015, making it more accessible. Major manufacturers include GSK, Teva, and Mylan, ensuring a reliable supply. For further details about dutasteride, visit the dutasteride oral capsule information page.

Dutamax

Dutamax, a brand containing the active ingredient dutasteride, is renowned for its efficacy in treating androgenetic alopecia and benign prostatic hyperplasia. Dutasteride, a 5-alpha-reductase inhibitor, significantly reduces dihydrotestosterone (DHT) levels, leading to a 23% reduction in total sperm count and a notable increase in hair count and thickness in clinical studies. Long-term safety data indicate a favorable safety profile, with ongoing research monitoring its long-term effects. The drug has shown promising results, with some studies demonstrating a significant increase in hair density and thickness within a few months of treatment. Dutasteride's market is expected to grow, supported by the availability of generics post-patent expiry. Additional insights into Dutamax can be explored through detailed resources on its uses.

Dinasteride

Dutasteride, particularly the brand Avodart, is renowned for its efficacy in treating benign prostatic hyperplasia (BPH) and male pattern hair loss. It inhibits both type 1 and type 2 5-alpha reductase enzymes, leading to a significant reduction of over 90% in dihydrotestosterone (DHT) levels, surpassing the 70% reduction achieved by finasteride. Approved by the FDA in 2001 for BPH, dutasteride has also shown promise in reducing the risk of prostate cancer by 23% over a four-year period, as seen in the REDUCE trial. Its long half-life of about 4 weeks allows for less frequent dosing once a steady state is reached. Despite its strong therapeutic benefits, dutasteride is not FDA-approved for treating male pattern hair loss in the US, although it is approved for this use in Japan and South Korea. For more detailed information about this potent hair loss treatment, visit the strongest and most powerful hair loss drug for men.

Atafen

Dutasteride, a 5-alpha reductase inhibitor, is primarily produced by well-known pharmaceutical companies such as GSK, Aurobindo Pharma, and Zydus. These companies ensure the drug's efficacy in reducing prostate volume by up to 90% and improving urinary flow in men with benign prostatic hyperplasia (BPH). Dutasteride significantly reduces serum DHT concentrations by 85-90% within the first few weeks of treatment. It is also known for its extensive hepatic metabolism and high protein binding, making it a reliable treatment option. The global dutasteride market is anticipated to grow, reflecting the drug's importance in managing BPH symptoms. For more information about Dutasteride, you can visit the RX List website.

Dutas T

Dutas T, a brand of dutasteride, is recognized for its high-quality production and widespread use in treating benign prostatic hyperplasia (BPH). Dutasteride, the active ingredient, was patented in 1993 by GlaxoSmithKline and approved for medical use in 2001. As of 2018, dutasteride was the 291st-most commonly prescribed medication in the US, with over 1 million prescriptions. India, a leading exporter of dutasteride, saw a 72% growth in exports from March 2023 to February 2024, with Dutas T being one of the prominent brands exported globally. For more detailed insights on dutasteride exports from India, visit the link.

Durajoint

Dutasteride, sold under brand names such as Avodart, is a highly effective medication for treating symptomatic benign prostatic hyperplasia (BPH) by inhibiting 5-alpha-reductase, which reduces DHT levels by up to 90% within 1-2 weeks of treatment. It has been shown to reduce the size of the prostate gland, enhance urinary flow, and decrease detectable prostate cancer incidence by 22.8% over 4 years, as evidenced by the REDUCE trial. Common adverse effects include impotence, decreased libido, and breast disorders. Metabolized by the liver through CYP3A4 enzymes, dutasteride has an elimination half-life of 4-5 weeks and exhibits high protein-binding affinity, with 99% binding to albumin. For comprehensive prescribing information, visit the FDA's official prescribing information.